Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer Clinical research trials and Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer. Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "S" Clinical Trials Conditions > Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer



Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

For Condition: Ovarian Cancer
Status: No longer recruiting
Sponsor(s): Sonus Pharmaceuticals ,
Synopsis: Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV platinum resistant ovarian cancer or primary peritoneal carcinoma.
Details: The goals of this study are to determine the objective response rate, to determine time to disease progression, duration of response, and survival, and to identify the maximum tolerated weekly dose and principal toxicities of S-8184 in this patient population.
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: Histologic diagnosis of ovarian cancer or primary peritoneal carcinoma Stage III or IV disease One and only one prior cytotoxic chemotherapy regimen which must have included a platinum agent Platinum resistant disease, defined as documented progression within six months of completion of first line therapy Adult (18 years of age or older) patients Adequate hematologic function (ANC greater than 1500 cells/mm3 and platelets greater than 100,000/mm3) Serum creatinine less than 2.0 mg/dL Total bilirubin less than 1.5 mg/dL; SGOT and SGPT less than 3 times the upper limit of institutional normal values ECOG performance status of 0 - 2 Bidimensional measurable or clinically evaluable disease Patients who have signed an IRB / Ethics Committee approved informed consent Life expectancy at least 12 weeks Patient has fully recovered from any previous surgery (at least 4 weeks since major surgery) Patient has a negative pregnancy test prior to study entry if premenopausal. (Patients of child bearing potential must use a medically effective form of contraception during the treatment.) Exclusion Criteria: Patients who have received any taxane-containing preparation including Taxol (paclitaxel) or Taxotere (docetaxel) Females who are pregnant or lactating Patients with peripheral neuropathy NCI-CTC grade 2 or greater Patients who have received wide-field radiation, cytotoxic chemotherapy or hormonal therapy within 4 weeks of study entry; or mitomycin or nitrosoureas within 6 weeks of study entry Patients who have had an investigational agent within 4 weeks of study entry Patients receiving concurrent anticonvulsants known to induce P450 isoenzymes
Total Enrollment: 

Location and Contact Information:


Additional Information:
Study ID Numbers:  SON-8184-1061; 
Study Start Date: March 2002
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034151

Other Ovarian Cancer Studies:
1. Vinorelbine and XR9576 to Treat Cancer

2. Acupuncture to Improve Quality of Life in Patients With Advanced Cancer

3. A Phase I Study of Infusional Chemotherapy with the P-Glycoprotein Antagonist PSC 833

4. A clinical efficacy study of an oral tyrosine kinase inhibitor of VEGFR-2 to treat recurrent or persistent small-volume epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer

5. A Phase I Study of Infusional Paclitaxel with the P-Glycoprotein Antagonist PSC 833

Related Studies:

Other Ovarian Cancer Clinical Trials
Other Clinical Trials
Other Clinical Trials

Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
Modify your Search

  Other Ovarian Cancer Clinical Trials
  Other Clinical Trials
  Other Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103